Efficient three-drug cocktail for disease induced by mutant superoxide dismutase

Annals of Neurology

Volumn 53, Issue 4, 2003, Pages 429-436

  Kriz, Jasna ^a   Gowing, Geneviève ^a   Julien, Jean Pierre ^a  

^a RESEARCH INSTITUTE OF THE MCGILL UNIVERSITY HEALTH CENTRE   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIBIOTIC AGENT; CALCIUM CHANNEL BLOCKING AGENT; COPPER ZINC SUPEROXIDE DISMUTASE; GLUTAMATE RECEPTOR ANTAGONIST; MINOCYCLINE; NIMODIPINE; RILUZOLE; SUPEROXIDE DISMUTASE; UNCLASSIFIED DRUG;

AMYOTROPHIC LATERAL SCLEROSIS; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CONTROLLED STUDY; DISEASE MODEL; DRUG EFFECT; DRUG EFFICACY; GLIOSIS; LONGEVITY; MOUSE; MUSCLE STRENGTH; NERVE CELL NECROSIS; NERVE DEGENERATION; NEUROPROTECTION; NONHUMAN; ONSET AGE; PRIORITY JOURNAL; SYMPTOM;

AGE OF ONSET; AMYOTROPHIC LATERAL SCLEROSIS; ANIMALS; ANTI-BACTERIAL AGENTS; AXONS; CALCIUM CHANNEL BLOCKERS; CASPASE 3; CASPASES; CYCLIN-DEPENDENT KINASE 5; CYCLIN-DEPENDENT KINASES; DISEASE MODELS, ANIMAL; DRUG THERAPY, COMBINATION; GLIOSIS; MICE; MICE, TRANSGENIC; MICROGLIA; MINOCYCLINE; MOTOR NEURONS; MUSCLE CONTRACTION; NEUROPROTECTIVE AGENTS; NIMODIPINE; RILUZOLE; SUPEROXIDE DISMUTASE;

EID: 0037381851     PISSN: 03645134     EISSN: None     Source Type: Journal    
DOI: 10.1002/ana.10500     Document Type: Article

References (44)

1. Cleveland DW, Rothstein JD. From Charcot to Lou Gehrig: deciphering selective motor neuron death in ALS. Nat Rev Neurosci 2001;2:806-819.
2. Julien J-P. Amyotrophic lateral sclerosis: unfolding the toxicity of the misfolded. Cell 2001;104:581-591.
3. Rowland LP, Shneider NA. Amyotrophic lateral sclerosis. N Eng J Med 2001;344:1688-1699.
4. Rosen DR, Siddique T, Patterson D, et al. Mutations in Cu/Zn superoxide dismutase gene are associated with familial amyotrophic lateral sclerosis. Nature 1993;362:59-62.
5. Cudkowicz ME, McKenna-Yasek D, Sapp PE, et al. Epidemiology of mutations in superoxide dismutase in amyotrophic lateral sclerosis. Ann Neurol 1997;41:210-221.
6. Gurney ME, Pu H, Chiu AY, et al. Motor neuron degeneration in mice that express a human Cu,Zn superoxide dismutase mutation. Science 1994;264:1772-1775.
7. Wong PC, Pardo CA, Borchelt DR, et al. An adverse property of a familial ALS-linked SOD1 mutation causes motor neuron disease characterized by vacuolar degeneration of mitochondria. Neuron 1995;14:1105-1116.
8. Brujin LI, Houseweart MK, Kato S, et al. Aggregation and motor neuron toxicity of an ALS-linked SOD1 mutant independent from wild-type SOD1. Science 1998;281:1851-1854.
9. Passinelli P, Houseweart MK, Brown RH, Cleveland DW. Caspase-1 and-3 are sequentially activated in a motor neuron death in Cu,Zn superoxidase dismutase-mediated familial amyotrophic lateral sclerosis. Proc Natl Acad Sci USA 2000;97: 13901-13906.
10. Rothstein JD, Van Kammen M, Levey AI, et al. Selective loss of glial glutamate transporter GLT-1 in amyotrophic lateral sclerosis. Ann Neurol 1995;38:73-84.
11. Kawamata T, Akiyama H, Yamada T, McGeer PL. Immunologic reactions in amyotrophic lateral sclerosis brain and spinal cord tissue. Am J Pathol 1992;140:691-707.
12. Schiffer D, Cordera S, Cavalla P, Mighelli A. Reactive astrogliosis of the spinal cord in amyotrophic lateral sclerosis. J Neurol Sci 1996;139:27-33.
13. Hall ED, Oostveen JA, Gurney ME. Relationship of microglial and astrocyric activation to disease onset and progression in a transgenic model of familial ALS. Glia 1998;23:249-256.
14. Kriz J, Nguyen MD, Julien J-P. Minocycline slows disease progression in a mouse model of amyotrophic lateral sclerosis. Neurobiol Dis 2002;10:268-278.
15. Van Den Bosch L, Tilkin P, Lemmens G, Robberecht W. Minocycline delays disease onset and mortality in a transgenic model of ALS. Neuroreport 2002;13:1-4.
16. Zhu S, Stavrovskaya IG, Drozda M, et al. Minocycline inhibits cytochrome c release and delays progression of amyotrophic lateral sclerosis in mice. Nature 2002;417:74-78.
17. Nguyen MD, Larivière R, Julien J-P. Deregulation of Cdk5 in a mouse model of ALS: toxicity alleviated by perikaryal neurofilament inclusions. Neuron 2001;30:135-147.
18. Gurney ME, Cutting FB, Zhai P, et al. Benefit of vitamin E, riluzole, and gabapentin in a transgenic model of familial amyotrophic lateral sclerosis. Ann Neurol 1996;39:147-157.
19. Li M, Ona VO, Guegan C, et al. Functional role of caspase-1 and caspase-3 in an ALS transgenic mouse model. Science 2000;288:335-339.
20. Nguyen MD, Boudreau M, Kriz J et al: Cell cycle regulators in neuronal death pathway of amytrophic lateral sclerosis caused by mutant superoxide dismutase 1. J Neurosc: 2003 (in press).
21. Goulden V, Glass D, Cunliffe WJ. Safety of long-term high- dose minocycline in the treatment of acne. Br J Dermatol 1996;134:693-695.
22. Amin AR, Attur MG, Thakker GD, et al. A novel mechanism of action of tetracyclines: effects on nitric oxide synthases. Proc Natl Acad Sci USA 1996;93:14014-14019.
23. Golub LM, Lee HM, Ryan ME, et al. Tetracyclines inhibit connective tissue breakdown by multiple non-antimicrobial mechanisms. Adv Dent Res 1998;12:12-26.
24. Yrjänheikki J, Keinänen R, Pellikka M, et al. Tetracyclines inhibit microglial activation and are neuroprotective in global brain ischemia. Proc Natl Acad Sci USA 1998;95: 15769-15774.
25. Yrjänheikki J, Tikka T, Keinanen R, et al. A tetracycline derivative, minocycline, reduces inflammation and protects against focal cerebral ischemia with a wide therapeutic window. Proc Natl Acad Sci USA 1999;96:13496-13500.
26. Sanchez Mejia RO, Ona VO, Li M, et al. Minocycline reduces traumatic brain injury-mediated caspase-1 activation, tissue damage, and neurological dysfunction. Neurosurgery 2001;48:1393-1399.
27. Chen M, Ona VO, Li M, et al. Minocycline inhibits caspase-1 and caspase-3 expression and delays mortality in a transgenic mouse model of Huntington disease. Nat Med 2000;6:797-801.
28. Du Y, Ma Z, Lin S, et al. Minocycline prevents nigrostriatal dopaminergic neurodegeneration in the MPTP model of Parkinson's disease. Proc Natl Acad Sci USA 2001;98:14669-14674.
29. Tikka T, Fiebich BL, Goldsteins G, et al. Minocycline, a tetracycline derivative, is neuroprotective against excitotoxicity by inhibiting activation and proliferation of microglia. J Neurosci 2001;21:2580-2588.
30. Bensimon G, Lacomblez L, Meininger VA. Controlled trial of riluzole in amyotrophic lateral sclerosis. ALS/Riluzole Study Group. N Eng J Med 1994;330:585-591.
31. Martin D, Thompson MA, Nadler JV. The neuroprotective agent riluzole inhibits release of glutamate and aspartate from slices of hippocampal area CA1. Eur J Pharmacol 1993;250:473-476.
32. Singh BN. The mechanism of action of calcium antagonists relative to their clinical applications. Br J Clin Pharmacol 1986; 21:109-121.
33. Miller RG, Shepherd R, Dao H, et al. Controlled trial of nimodipine in amyotrophic lateral sclerosis. Neuromuscul Disord 1996;6:101-104.
34. Siklos L, Engelhardt J, Harati Y, et al. Ultrastructural evidence for altered calcium in motor nerve terminals in amyotrophic lateral sclerosis. Ann Neurol 1996;39:209-216.
35. 2+ currents in a motoneuron cell line. Ann Neurol 1995;37:102-109.
36. Engelhardt JI, Siklos L, Komuves L, et al. Antibodies to calcium channels from ALS patients passively transferred to mice selectively increase intracellular calcium and induce ultrastructural changes in motoneurons. Synapse 1995;20:185-199.
37. Cano-Abad MF, Villaroya M, Garcia AG, et al. Calcium entry through L-type calcium channels causes mitochondrial disruption and chromaffin cell death. J Biol Chem 2001;43: 39695-39704.
38. Korenkov AI, Pahnke J, Frei K, et al. Treatment with nimodipine or mannitol reduces programmed cell death and infarct size following focal cerebral ischemia. Neurosurg Rev 2000;23:145-150.
39. Kriz J, Ž upan G, Simonić A. Differential effects of dihydropyridine calcium channel blockers in kainic acid-induced seizures in rats. Epilepsy Res 2002 (in press).
40. Mattsson P, Janson AM, Aldskogius H, Svensson M. Nimodipine promotes regeneration and functional recovery after intracranial facial nerve crush. J Comp Neurol 2001;437:106-117.
41. Barneoud P, Curet O. Beneficial effects of lysine acetylsalicylate, a soluble salt of aspirin, on motor performance in a transgenic model of amyotrophic lateral sclerosis. Exp Neurol 1999;155:243-251.
42. Trieu VN, Liu R, Liu X-P, Uckun FM. A specific inhibitor of Janus kinase-3 increases survival in a transgenic mouse model of amyotrophic lateral sclerosis. Biochem Biophys Res Commun 2000;267:22-25.
43. Canton T, Bohme GA, Boireau A, et al. RPR119990, a novel α-amino-3-hydroxy-5-methyl-4-isoxazolepropionic acid antagonist: synthesis, pharmacological properties, and activity in an animal model of amyotrophic lateral sclerosis. J Pharmacol Exp Ther 2001;299:314-322.
44. Klivenyi P, Ferrante RJ, Matthews RT, et al. Neuroprotective effects of creatine in a transgenic animal model of amyotrophic lateral sclerosis. Nat Med 1999;5:347-350.